GWP42003-P (cannabidiol) is believed to affect several pharmacological pathways and may have the potential to modulate some of the pathophysiological mechanisms thought to underlie the neurobehavioral deficits present in Rett Syndrome including excitatory/inhibitory neuronal imbalance, neuroinflammation and antioxidant dysfunction. The aim of the clinical trial is to evaluate the safety and efficacy of GWP42003-P in reducing symptom severity in females, aged 4 to 18 years, with Rett S
The effect of two doses will be compared with a placebo control across a 24-week treatment period. Patients completing the study will have the opportunity to take part in a 6-month extension study where all patients will receive GWP42003-P. In total, approximately 252 patients are expected to be included.
One of the eligibility requirements is for patients to refrain from taking medicinal cannabis, cannabinoid-based medications or cannabidiol oral solutions for at least 3 months prior to screening in the study. The full list of eligibility criteria can be found on clinicaltrials.gov [ClinicalTrials.gov Identifier: NCT03848832].
US trial sites in Cincinnati, OH and Greenwood, SC are now recruiting.
UK trial sites in Liverpool and London are expected to open in June and July 2019 respectively.
For further information, please contact Reverse Rett:
Tel: 0161 434 0585
Further US sites are expected to open from June 2019 onwards in Nashville, TN; Houston, TX; Chicago, IL; San Diego, CA; Birmingham, AL; Philadelphia, PA; Boston, MA; St Paul, MN; Aurora, CO; Baltimore, MD; New York, NY; St Louis, MO.
GW is looking forward to working with the Rett Community on this important study investigating the safety and efficacy of GWP42003-P in people with Rett Syndrome.